NCNA NuCana plc
USHealthcareAs of 2026-07-10 16:00
Why NCNA matters now
NuCana plc (NCNA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.34 with +8.06% on the session and $8.1M in market capitalization; recent performance reads 1-month -3.54% and YTD -46.94%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.9M, and EPS of $-1.07. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -85.6%.
The latest indexable market news headline is "NuCana Appoints Ian Webster as Chief Financial Officer" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Bruce Theresa Margaret Ms filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.24
P/S
0.00
EV/EBITDA
0.54
DCF Value
$9.20
FCF Yield
-85.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-153.8%
ROA
-111.6%
ROIC
-90.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.9M | $-1.07 |
| Q4 2025 | $0.00 | $-2.5M | $-0.66 |
| FY 2025 | $0.00 | $-29.4M | $-7.75 |
| Q3 2025 | $0.00 | $-281.0K | $-0.08 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
—
Beta
2.18
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.